Therapeutic window of bradykinin B2 receptor inhibition after focal cerebral ischemia in rats

In conclusion, the current study shows that the therapeutic window of B2 receptor inhibition extends for up to 6.5 h after MCAo. Our data therefore suggest that inhibition of kinin B2 receptors represents a treatment strategy for ischemic stroke which may warrant clinical validation.